Related Experiment Video
Updated: Jul 31, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study
N Furusyo1, J Hayashi, K Kakuda
1Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
Insights
Newly acquired hepatitis C virus (HCV) infection continues in hemodialysis patients despite blood screening. Abnormal ALT levels in these patients are linked to HCV chronicity, highlighting ongoing transmission risks.
Area of Science:
- Hepatology
- Infectious Diseases
- Nephrology
Background:
- Hepatitis C virus (HCV) screening of blood products was implemented in Japan in 1989.
- Hemodialysis patients are at increased risk for HCV infection due to frequent medical procedures and potential blood exposure.
Purpose of the Study:
- To determine the incidence of newly acquired HCV infection in hemodialysis patients.
- To characterize the clinical features of these new HCV infections.
- To assess the impact of anti-HCV screening on HCV acquisition in this population.
Main Methods:
- Prospective survey of 269 hemodialysis patients from 1990 to 1998.
- Serial serum samples analyzed for HCV RNA (RT-PCR) and anti-HCV (ELISA).
- Follow-up over a mean period of 6.6 years.
Main Results:
- Newly acquired HCV infection occurred in 15.4% of patients (26/169) without prior infection, with an annual incidence of 2.59%.
- Only four patients had a history of blood transfusion, with one receiving transfusion after 1992.
- Persistent HCV viremia was observed in 65.4% of infected patients, with prolonged ALT abnormalities in some, though ALT eventually normalized in all chronic cases.
Conclusions:
- Newly acquired HCV infection remains a concern in hemodialysis patients even after anti-HCV blood product screening.
- Abnormal alanine aminotransferase (ALT) levels in these patients are associated with HCV chronicity.
- Ongoing vigilance and infection control measures are crucial in hemodialysis settings.
Objectives:
The aims of this prospective survey were to determine the incidence and clinical characteristics of newly acquired hepatitis C virus (HCV) infection in hemodialysis patients after the start of antibody to HCV (anti-HCV) screening for blood products in Japan in 1989.
Methods:
In serial serum samples from 269 hemodialysis patients who were followed over a mean period of 6.6 yr (+/- 2.1 yr) from 1990 to 1998, HCV RNA and anti-HCV were detected by reverse transcription-polymerase chain reaction and second generation ELISA, respectively.
Results:
During the observation period, newly acquired HCV infection was found in 26 (15.4%) of the 169 hemodialysis patients without anti-HCV or HCV RNA at entry, an annual incidence rate of 2.59%. Of these 26, only four had a history of blood transfusion, one of whom had received the blood transfusion after 1992, the year in which screening of blood products for anti-HCV by second-generation ELISA was introduced in Japan. Persistent HCV viremia was found in 17 (65.4%) of the 26 patients; the other nine (34.6%) had transient HCV infection. The mean period of continuous ALT abnormality was significantly longer in the former (12.4+/-13.6 months) than in the latter (1.9+/-3.5 months) (p = 0.0067). However, only three (17.6%) of 17 patients with chronic HCV viremia had continuous ALT abnormality for more than 24 months; in all of them, ALT eventually normalized.
Conclusions:
These findings indicate that newly acquired HCV infection has continued to occur in hemodialysis patients after the initiation of anti-HCV screening of blood products and that the abnormal ALT found in these patients is related to HCV chronicity.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Hemodialysis III: Nursing Management
Kidney Transplant I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Hepatitis
Viral Hepatitis I: Introduction

